Tomivosertib NEW
| Price | $42 | $129 | $198 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-21 |
Product Details
| Product Name: Tomivosertib | CAS No.: 1849590-01-7 |
| Purity: 97.34% | Supply Ability: 10g |
| Release date: 2025/10/21 |
Product Introduction
Bioactivity
| Name | Tomivosertib |
| Description | Tomivosertib (eFT508) is a potent and highly selective MNK1 and MNK2 inhibitor with an IC50 value of 1-2 nM. |
| Cell Research | TMD8 cells are treated with the indicated concentrations of eFT508 for 24 h. Cell lysates are subjected to m7-GTP Sepharose pull-down and bound proteins are analyzed by immunoblotting with the indicated antibodies. (Only for Reference) |
| In vitro | Tomivosertib has a half-maximal inhibitory concentration (IC50) of 1-2 nM against both MNK isoforms in enzyme assays and inhibits the kinase through a reversible, ATP-competitive mechanism of action. Treatment of tumor cell lines with Tomivosertib leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50 = 2-16 nM). In a panel of ~50 hematological cancers, Tomivosertib shows anti-proliferative activity against multiple DLBCL cell lines. Sensitivity to Tomivosertib in TMD8, OCI-Ly3 and HBL1 DLBCL cell lines is associated with dose-dependent decreases in production of pro-inflammatory cytokines including TNFα, IL-6, IL-10 and CXCL10[1]. |
| In vivo | eFT508 is well-tolerated and shows efficacy against MyD88-mutant DLBCL models in vivo. Significant anti-tumor activity of eFT508 is observed in the TMD8 and HBL-1 ABC-DLBCL models(subcutaneous human lymphoma xenograft models), both of which harbor activating MyD88 mutations[1]. |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : <1 mg/mL DMSO : 11 mg/mL (32.32 mM), Sonication is recommended. Ethanol : <1 mg/mL |
| Keywords | Tomivosertib | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | MNK2 | MNK1 | MNK | Mitogen activated protein kinase interacting kinase | MAPK interacting kinase | MAP kinase interacting kinase | Inhibitor | inhibit | eFT-508 | eFT 508 |
| Inhibitors Related | LSD1-IN-24 | PD-1/PD-L1-IN-9 | Sulfamethoxypyridazine | BMS-202 | PD-1-IN-22 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | IMMH 010 maleate | EB1 | Camrelizumab | LSD1-IN-27 | MK2-IN-3 hydrate | PD-L1-IN-3 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3100.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $9.80/1.8KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY